Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 34
- Registration Number
- NCT03667014
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 321
- Registration Number
- NCT03633617
- Locations
- 🇬🇧
Regeneron Study Site, Barnsley, Yorkshire, United Kingdom
🇺🇸Regeneron Study Site #2, Chicago, Illinois, United States
🇺🇸Regeneron Study Site #1, Chicago, Illinois, United States
Dupilumab for Aspirin-exacerbated Respiratory Disease
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT03595488
- Locations
- 🇺🇸
Rochester Regional Health - Allergy/Immunology, Rochester, New York, United States
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT03558997
- Locations
- 🇨🇦
Regeneron Investigational Site, Québec, Quebec, Canada
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
- Conditions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 858
- Registration Number
- NCT03428646
- Locations
- 🇨🇦
Regeneron Investigational Site, Quebec, Canada
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2021-10-04
- Target Recruit Count
- 72
- Registration Number
- NCT03389893
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Stanford University, Stanford, California, United States
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
- Conditions
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 296
- Registration Number
- NCT03387852
- Locations
- 🇲🇽
Investigational Site Number 4840004, Durango, Mexico
🇺🇸Investigational Site Number 8400014, Milwaukee, Wisconsin, United States
🇺🇸Investigational Site Number 8400021, Ann Arbor, Michigan, United States
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 60
- Registration Number
- NCT03359356
- Locations
- 🇺🇸
The Rockefeller University Laboratory for Investigative Dermatology, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Molecular Signatures in Inflammatory Skin Disease
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Prof. Dr. Stephan Weidinger
- Target Recruit Count
- 300
- Registration Number
- NCT03358693
- Locations
- 🇩🇪
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT03346434
- Locations
- 🇩🇪
Regeneron Investigational site, Muenchen, Germany
🇬🇧Regeneron Investigational Site, Sheffield, South Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.